Accord Group, a top notch private sector firm founded by S. Jagathrakshakan, forays into pharma business with a domain knowledge the company already has in areas like Healthcare, Hospitality, Information Technology, Realty, Power Generation, Education, Distilleries, Print and Visual Media. Headquartered in Chennai, Accord Group now enters the Pharma Business with a bang as Accord Life Spec Pvt. Ltd (Accord Pharma) with a major focus on research and development, manufacturing and supply of Sterile and non-sterile formulation products and API across countries, besides planning to make a strong impact in Indian pharma market.
According to Mr. Manish Choube, Global CEO, Accord Life Spec, and Mr. Satessh Singh, Senior Vice-President, Sales and Marketing, Accord Pharma-India Business, there are plans to make the company a global specialty pharmaceutical entity in terms of innovation of products for patients in the current challenging and competitive pharmaceutical environment.
This is driven by a strong commitment to quality compliance and to operating with the highest standards of ethics and integrity,” the two top officials said and added, `we are well-versed with the expectations and trust that our customers and stakeholders have in us and we work towards creation of a healthier world.” They mentioned, “Company will launch various products in international markets including USA, Europe and various other countries from next year”.
As a first step, Accord Group is venturing into Indian Market with the introduction of two key therapies Oncology and Nephrology to fill the gap between Quality and Demand. The products range deals with treatment during blood cancer, breast cancer, lung cancer, hemodialysis, kidney transplant and renal medicines.
About the formulation products research & development and manufacturing facilities, they said, ‘The world class facility at Oragadam, Chennai, has the required modern equipments for design and development, manufacturing and supply of Parenteral & Oral Solid Dosages Formulations (Oncology and Non-Oncology).”
The two experts further said, “Our export-oriented manufacturing facility (EOU) has been built to the strictest specifications and in accordance with the principles of current Good Manufacturing Practices as required by the guidelines of the USFDA, UK-MHRA, PIC/S, TGA-Australia, Health Canada, ANVISA-Brazil, MCC-South Africa, India-DCA and other regulatory agencies across the globe.”
Accord Life Spec’s world class Active Pharmaceutical Ingredients (APIs) / Biotech Research and Development Centre at Puducherry has a focus to develop APIs that are competitive and profitable in the long run.
“Accord Life Spec continually seeks new opportunities to grow its business trajectory through strategic partnerships with companies seeking support in product development and manufacturing for oncology and other formulation products” they said.